Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Profitable Debt-Free Cash-Rich CPH at 0.8x its EBITDA!!!

<< Previous

Bullboard Posts

Next >>

Comment by Stocker46on Mar 19, 2021 5:52pm

241 Views

Post# 32843345

RE:RE:RE:RE:RE:RE:RE:RE:Profitable Debt-Free Cash-Rich CPH at 0.8x its EBITDA!!!

Good one Northforce, I should have been more specific. I bought about one third of my original position on thursday (just in case they surprised me with a better 4th Q performance than I anticipated .. which they surely did) & the rest this AM.

In hindsite I should have just kept my oringinal purchase, but after earning of $.4 M & $1.6 M in the previous 2 quarters. there's no way I would have predicted $5.2 M in 4th Q.

<< Previous

Bullboard Posts

Next >>

Critical materials crisis: Diversifying away from China’s monopoly